HUMA is trading 5.06% up at $0.65 as the stock shows signs of stabilization following a sharp decline linked to a proposed public offering of common stock.
- The recent volatility was triggered by Humacyte's announcement of a proposed underwritten public offering, which pressured shares during the June 25 after-hours session.
- Market analysts suggest the current bounce is a technical stabilization after the offering-related selloff, as no fresh fundamental catalysts or company-specific updates have been reported.